Evolocumab Is Potentially the Biggest Pipeline Product for Amgen (AMGN), Jefferies Notes
Tweet Send to a Friend
Jefferies analyst Eun Yang reiterated a Buy rating and $142 price target on Amgen (NASDAQ: AMGN) following cardiologists discussion on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
